<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02986880</url>
  </required_header>
  <id_info>
    <org_study_id>2011/08</org_study_id>
    <secondary_id>2011-000889-35</secondary_id>
    <nct_id>NCT02986880</nct_id>
  </id_info>
  <brief_title>Effect of Type-A Botulinum Toxin in the Post-radiosurgical Neck Contractures</brief_title>
  <official_title>A Dose-response, Randomized, Double-blind Study to Evaluate the Effect of Type-A Botulinum Toxin in the Post-radiosurgical Neck Contractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to estimate the efficiency and to determine the optimal
      dose of Botulinum toxin A, administered by intramuscular way in cervical spasms after
      radiotherapy, as well as the optimal sites for these injections.

      The concerned muscular groups are the sternocleidomastoid (SCM), the trapezius muscle and the
      splenius capitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">January 10, 2014</completion_date>
  <primary_completion_date type="Actual">January 10, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cervical mobility degree</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire Module for Head and Neck Cancer (QLQ-H&amp;N35)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Cervical Spasm</condition>
  <condition>Radiotherapy Side Effect</condition>
  <condition>Botulinum Toxin</condition>
  <arm_group>
    <arm_group_label>Group D1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving the toxin in SCM and the placebo in trapezius muscle and splenius capitis. Patients receiving the dose of 30 units (U) at injection point, totalling 120 U.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis. Patients receiving the dose of 60 units (U) at injection point, totalling 240 U.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis. Patients receiving the dose of 100 units (U) at injection point, totalling 400 U.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 30 units (U) at injection point, totalling 180 U.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 60 units (U) at injection point, totalling 360 U.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 100 units (U) at injection point, totalling 600 U.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 30 units (U) at injection point, totalling 300 U.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 60 units (U) at injection point, totalling 600 U.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 100 units (U) at injection point, totalling 1000 U.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receiving placebo in the third muscles groups</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin A</intervention_name>
    <arm_group_label>Group D1</arm_group_label>
    <arm_group_label>Group D2</arm_group_label>
    <arm_group_label>Group D3</arm_group_label>
    <arm_group_label>Group A1</arm_group_label>
    <arm_group_label>Group A2</arm_group_label>
    <arm_group_label>Group A3</arm_group_label>
    <arm_group_label>Group F1</arm_group_label>
    <arm_group_label>Group F2</arm_group_label>
    <arm_group_label>Group F3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injection of sodium chloride (NaCl) 9/1000</description>
    <arm_group_label>Group P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients from 18 to 75 years old;

          -  malignant Tumor of aerodigestive ways, in forgiveness;

          -  Treatment containing the external radiotherapy ended since &gt; 6 months

          -  Life expectancy &gt; 6 months;

          -  patient complaining from cervical spasms with functional disability;

          -  Negative Pregnancy test;

          -  Women under effective contraception;

          -  Patients benefiting from a national insurance scheme;

          -  Patient having given a written consent.

        Exclusion Criteria:

          -  Cervico-facial Surgery with reconstruction by pedicled flap

          -  Implantable Chamber with catheter in the internal jugular vein near the spasm;

          -  Muscular, neurological Pathology or malformative pulling a disorder of perception of
             the pain, an amyotrophy, a muscular weakness affecting the cervical axis or the upper
             limbs;

          -  Disorder generalized by the muscular activity (ex myasthenia);

          -  Cervical osseous or muscular Pathology pulling pains and disability before the
             beginning of the treatment (cervical degenerative osteoarthritis diagnosed to the
             cervical radiography, the slipped disc);

          -  Previous cervical injection of botulinum toxin ;

          -  Local Infection at the level of one of the sites proposed for injection;

          -  Histories of epilepsy;

          -  Patients presenting a hypersensitivity to the botulinum neurotoxin A or in one of its
             excipients;

          -  Patients under anticoagulation therapy, Under antibiotic treatment by aminoglycosides
             or amino 4 quinoline, under myorelaxant treatment or that must undergo an intervention
             with curarisation;

          -  Patients for whom a surgical operation is planned in the zone interested in the
             treatment

          -  Pregnant or breast-feeding Women;

          -  Patients for whom questionnaires will not be assessable (handicaps of communication,
             patient not speaking French, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Bach</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Foch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2016</study_first_submitted>
  <study_first_submitted_qc>December 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2016</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contracture</mesh_term>
    <mesh_term>Torticollis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

